Some examples and use cases from the internet:

Some examples and use cases from the internet:

• achievement of expected results as set out by donor objectives and country strategies,
• Ritonavir dosed as a pharmacokinetic enhancer or as an antiretroviral agent inhibits CYP3A4 and as a result is expected to increase the plasma concentrations of calcium channel antagonists.
• Ritonavir dosed as an antiretroviral agent is likely to inhibit CYP2D6 and as a result is expected to increase concentrations of haloperidol, risperidone and thioridazine.
• Actual results are as expected in the "Expected result" description;
• Indinavir inhibits CYP3A4 and as a result is expected to increase the plasma concentrations of these anticonvulsants.
• It took a little longer than we thought, but the result is as expected.
• Interaction with indinavir/ ritonavir not studied Ritonavir induces glucuronidation and as a result is expected to decrease the plasma concentrations of atovaquone.
• If there were any consistency to the analysis criteria, we would have to acknowledge that the results were, as expected, sparse.

• Interaction with indinavir/ ritonavir not studied Ritonavir induces glucuronidation and as a result is expected to decrease the plasma concentrations of atovaquone.
• Ritonavir dosed as a pharmacokinetic enhancer or as an antiretroviral agent inhibits CYP3A4 and as a result is expected to increase the plasma concentrations of carbamazepine.
• Indinavir inhibits CYP3A4 and as a result is expected to increase the plasma concentrations of these anticonvulsants.
• Ritonavir dosed as a pharmacokinetic enhancer or as an antiretroviral agent inhibits CYP3A and as a result is expected to increase the plasma concentrations of dexamethasone.
• Ritonavir dosed as a pharmacokinetic enhancer or as an antiretroviral agent inhibits CYP3A4 and as a result is expected to increase the plasma concentrations of calcium channel antagonists.
• Ritonavir dosed as a pharmacokinetic enhancer or as an antiretroviral agent induces oxidation by CYP2C9 and glucuronidation and as a result is expected to decrease the plasma concentrations of anticonvulsants.
• It took a little longer than we thought, but the result is as expected.
• Ritonavir dosed as an antiretroviral agent is likely to inhibit CYP2D6 and as a result is expected to increase concentrations of haloperidol, risperidone and thioridazine.